Share Price, page-2833

Interesting article for those that keep and eye on M & A activity:

https://www.nature.com/articles/s41587-022-01529-2

Some points below:

* At its current pace, 2022 is set to be the slowest year for mergers and acquisitions (M&A) since 2018.

* On paper, record big pharma cash reserves, a steep, fast-approaching patent cliff and low public biotech valuations should equal frenzied buying

* “There’s no sense of urgency on big pharma’s side,” says one public market investor. Most of those that are shopping are buying marketed or close-to-market assets that immediately fill revenue gaps.

* Big pharma’s patent cliff “won’t be solved by buying a phase 2 company,”

* If they like it, they will partner. “Often big pharma seems to prefer to invest in just the asset, rather than take on an entire company,” with associated staff and R&D costs,